KRAS and neoplasm: In clinical studies, gefitinib induces initial tumor regressions in lung cancer patients with EGFR activating mutations, including Exon19 Del, L858R mutation, and has no significant anti-tumor activity in lung cancer patients with KRAS mutation [32].